Irreversible Electroporation (NanoKnife® System)

Introduction

Irreversible electroporation is a surgical method used to destroy soft tissue (ablation). It is considered a non-thermal type of ablation since it does not produce heat to destroy tissue but uses direct-current electrical fields applied to soft tissue. These direct-current electrical fields create very small holes in the cell membranes of the tissue where it is applied causing the cell to become more porous, which results in the death of the cell. When these electrical fields are delivered for a long enough time and at a high enough energy level, they will permanently damage the tissue. This method of treatment is unproven. More studies are needed to show that it is safe and effective.

Note: The Introduction section is for your general knowledge and is not to be taken as policy coverage criteria. The rest of the policy uses specific words and concepts familiar to medical professionals. It is intended for providers. A provider can be a person, such as a doctor, nurse, psychologist, or dentist. A provider also can be a place where medical care is given, like a hospital, clinic, or lab. This policy informs them about when a service may be covered.
Irreversible electroporation (NanoKnife® System) is considered investigational for all indications, including but not limited to, ablation of soft tissue or of solid organs, such as the liver or pancreas.

### Coding

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT</td>
<td>Ablation, irreversible electroporation; 1 or more tumors per organ, including imaging guidance, when performed, percutaneous</td>
</tr>
<tr>
<td>0600T</td>
<td>Ablation, irreversible electroporation; 1 or more tumors, including fluoroscopic and ultrasound guidance, when performed, open</td>
</tr>
</tbody>
</table>

**Note:** CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

### Related Information

N/A

### Evidence Review

#### Description

“The NanoKnife® System delivers a series of high voltage direct current electrical pulses between two electrodes placed within a target area of tissue.”¹ These electrical pulses create nanopore or micropore defects in the cell membrane, increasing the cell’s permeability which results in cell death. Once enough high voltage electrical pulses have been delivered, the cells
become irreversibly damaged. This non-thermal ablation technique is called irreversible electroporation.\textsuperscript{2,3}

**Background**

“The NanoKnife® System delivers a series of high voltage direct current electrical pulses between two electrodes placed within a target area of tissue.”\textsuperscript{1} These electrical pulses create nanopore or micropore defects in the cell membrane, increasing the cell’s permeability which results in cell death. Once enough high voltage electrical pulses have been delivered, the cells become irreversibly damaged. This non-thermal ablation technique is called irreversible electroporation.\textsuperscript{2,3}

It is proposed that this technique causes less damage to tissue compared with thermal or radiation procedures. The reported benefit of this type of minimally invasive ablation procedure is that it can be used in areas where precision and preservation of the surrounding tissue, blood vessels, and nerves is paramount. This conservation of critical structures is thought to lead to fewer adverse effects.\textsuperscript{4} It does require the use of general anesthesia and complete neuromuscular blockade (paralysis) due to the muscle contractions brought about by the strong electric fields created by IRE and the direct stimulation of the neuromuscular junction. It is performed by an interventional radiologist along with an anesthesiologist.\textsuperscript{5}

The procedure involves percutaneously placing several electrodes in the form of long needles around the targeted area of soft tissue. It can also be used in open or laparoscopic intraoperative procedures. Imaging such as ultrasound, magnetic resonance or tomography is used to guide the placement of the needles. The needles are then connected to the IRE generator.\textsuperscript{6} The NanoKnife® System consists of a console with a screen, generator, foot pedal, electrode probe spacer and single-use, disposable electrode probes. The system uses a proprietary algorithm to generate a treatment plan. Depending on the size of the treatment field and the number of electrodes used, the ablation procedure takes place between one and 10 minutes. The electrodes may be repositioned under imaging guidance to extend the targeted treatment area until an entire tumor and appropriate treatment margins have been ablated.\textsuperscript{7}

“The NanoKnife® System has been cleared by the FDA for the surgical ablation of soft tissue. It has not received clearance for the therapy or treatment of any specific disease or condition.”\textsuperscript{45} Some of the areas where IRE has been studied is in the ablation of renal masses, liver lesions, pancreatic adenocarcinoma, lung cancer, prostate cancer, uveal melanoma, and thyroid cancer, among others.
The following are considered contraindications by the manufacturer for using the NanoKnife® System: ablation of lesions in the presence of any implanted electronic devices such as cardiac pacemakers or defibrillators, ablation of lesions near any implanted metal or electronic device, ablation of lesions of the eye, or use in a patient with a history of epilepsy, cardiac arrhythmia, or myocardial infarction. The manufacturer also notes that some of the adverse effects that have been associated with the use of the NanoKnife® system include: arrhythmias, muscle contractions, hemorrhage, mechanical perforation, pneumothorax, infection, and damage to vital anatomical structures such as nerves, blood vessels, ducts or glands.1

Summary of Evidence

For individuals with primary or metastatic liver tumors or locally advanced pancreatic adenocarcinoma, the evidence includes several non-randomized, retrospective cohort studies, comparative registry studies, retrospective single-arm studies, and prospective single-arm studies, all of which had limitations (Narayanan et al. [2017], Cannon et al. [2013], Dollinger et al. [2015], Niessen et al. [2016], and Martin et al. [2015, 2013, 2012]). All sample sizes were small, none of the studies were randomized prospective comparative studies, and follow-up has been limited to short-term intervals. These studies suggest the irreversible electroporation ablation procedure using the NanoKnife® System may be safe, somewhat low-risk, and may enhance survival for small tumors <3 cm, especially for tumors that are located near critical structures that have proven difficult to treat with other ablative methods.

For individuals with prostate cancer, the evidence includes 4 single arm prospective studies (Dong, et al. [2018], Valerio et al. [2017, 2014], Ting [2016]) These studies addressed safety and efficacy and adverse effects. Although IRE in the treatment of localized prostate cancer appears to be safe and has low urogenital toxicity, additional studies are needed to optimize patient selection and treatment parameters. The European Section of Urotechnology (ESUT) position statement (2018) stated that further prospective trials are required to assess medium to long term disease control of different ablative modalities for focal treatment of prostate cancer. There are no randomized trial comparisons to conventional radical prostatectomy or radiotherapy and there is limited oncologic follow-up. Wendler (2017) concluded, “...there is not enough evidence of its effectiveness or adverse effects to justify its use as a definitive treatment option for localized prostate cancer.”36

For individuals with renal cell carcinoma (RCC), the evidence includes one prospective single arm phase II study, a single arm prospective study, and a retrospective single arm study (Wendler [2018], Canvasser [2017], Trimmer [2015]). IRE appeared to be safe in the treatment of RCC but was found to require substantial procedural effort. There was also a high rate of microscopic
incomplete ablation found after IRE. Larger series, longer follow-up, and comparisons to conventional nephrectomy are needed.

For individuals with unresectable lung malignancies, the evidence includes a single arm prospective phase II trial and case series (Ricke [2015], Usman [2012]). Expected efficacy of the phase II trial was not met and the trial was stopped prematurely. The case series of 2 patients demonstrated the tumors both recurred at 6 months of follow-up.

Additional well-designed, randomized controlled studies are needed to firmly establish the safety and efficacy of IRE. Some of the current identified challenges are: the procedure itself has been found to be technically demanding, requiring technical skill and precision for the placement of multiple probes, histologic assessment and imaging of ablation zones following IRE need to be better defined due to the apoptotic cell death versus the coagulation necrosis seen with thermal ablation techniques in order to measure standardized response rates and to best determine local tumor recurrence. Currently, there is only one Investigational Device Exemption in place for the treatment of prostate cancer, so all other investigations into other tissue specific conditions are considered off-label.

**Ongoing and Unpublished Clinical Trials**

Some ongoing trials that might influence this policy are listed in [Table 1](#).

**Table 1. Summary of Key Trials**

<table>
<thead>
<tr>
<th>NCT No.</th>
<th>Trials Name</th>
<th>Planned Enrollment</th>
<th>Completion Date</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ongoing</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT02041936</td>
<td>Outcomes of Ablation of Unresectable Pancreatic Cancer Using the NanoKnife Irreversible Electroporation (IRE) System</td>
<td>12</td>
<td>Dec 2021</td>
</tr>
<tr>
<td>NCT03614910</td>
<td>Ablation of Unresectable Locally Advanced Pancreatic Cancer with NanoKnife® Irreversible Electroporation (IRE) System: Response and Tolerability</td>
<td>30</td>
<td>May 2023</td>
</tr>
<tr>
<td>NCT03105921</td>
<td>Irreversible Electroporation (NanoKnife®) for the Treatment of Pancreatic Adenocarcinoma</td>
<td>20</td>
<td>June 2022</td>
</tr>
</tbody>
</table>
## Practice Guidelines and Position Statements

### National Institute for Health and Care Excellence (NICE)

In 2019, the NICE updated the recommendation for IRE for primary liver cancer stating, “Evidence on the safety of irreversible electroporation for primary liver cancer shows serious but infrequent and well-recognized complications. Evidence on its efficacy is inadequate in quantity and quality” and concluded that the procedure should only be used in the context of research.\(^{19}\)

The National Institute for Health and Care Excellence (NICE) (2017) recommended that irreversible electroporation (IRE) for treating pancreatic cancer only be used in the context of research. The recommendation stated: “current evidence on the safety and efficacy of IRE for treating pancreatic cancer is inadequate in quantity and quality.”\(^{27}\) They noted that further research in the form of randomized controlled trials is needed.

In 2016, the NICE recommendation stated “the current evidence on the safety and efficacy of IRE for treating prostate cancer is inadequate in quantity and quality.” Indicating that the procedure should only be used in the context of research. Recommendations were made that RCTs comparing the procedure with current standards of care be performed.\(^{30}\)

In 2013, the NICE recommendation stated “current evidence on the safety and efficacy of irreversible electroporation for treating renal cancer is inadequate in quantity and quality” indicating that the procedure should only be used in the context of research. In the same year, they made the same recommendation for IRE for treating liver metastases, primary liver cancer, and for treating primary lung cancer and metastases in the lung.

### National Comprehensive Cancer Network

National Comprehensive Cancer Network (NCCN) clinical practice guideline (Version 2.2021) on “Pancreatic Adenocarcinoma” states that IRE has been used in patients with locally advanced pancreatic cancer and may be considered safe and extend survival. “However, due to concerns
about complications and technical expertise, the panel does not currently recommend IRE for treatment of locally advanced pancreatic cancer.\textsuperscript{38}

**Medicare National Coverage**

There is no national coverage determination.

**Regulatory Status**

In 2011 NanoKnife\textsuperscript{®} System (Angiodynamics, Inc.) was cleared through the 510(k) process (K102329) as a class II device. It is described as a low energy direct current non-thermal ablation device and substantially equivalent to its predecessors, the Oncobionic System with 6 Probe Output (K080202) and the Oncobionic System (K080376). It is intended for the surgical ablation of soft tissue and classified as an electrosurgical cutting and coagulation device.\textsuperscript{45}

In May 2011, the FDA granted Investigational Device Exemption (IDE) approval for a clinical trial of the NanoKnife\textsuperscript{®} for the ablation of low-risk, localized prostate cancer.

Product Code: OAB

**References**


### History

<table>
<thead>
<tr>
<th>Date</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>10/01/19</td>
<td>New policy, approved September 10, 2019, effective January 3, 2020. Add to Surgery section. The use of irreversible electroporation (IRE) (ie, NanoKnife® System) is considered investigational for all indications.</td>
</tr>
<tr>
<td>07/01/20</td>
<td>Coding update. Added codes 0600T and 0601T. Removed 32999, 47399, 48999, and 53899.</td>
</tr>
</tbody>
</table>

**Disclaimer:** This medical policy is a guide in evaluating the medical necessity of a particular service or treatment. The Company adopts policies after careful review of published peer-reviewed scientific literature, national guidelines and local standards of practice. Since medical technology is constantly changing, the Company reserves the right to review and update policies as appropriate. Member contracts differ in their benefits. Always consult the member benefit booklet or contact a member service representative to determine coverage for a specific medical service or supply. CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). ©2021 Premera All Rights Reserved.

**Scope:** Medical policies are systematically developed guidelines that serve as a resource for Company staff when determining coverage for specific medical procedures, drugs or devices. Coverage for medical services is subject to the limits and conditions of the member benefit plan. Members and their providers should consult the member
benefit booklet or contact a customer service representative to determine whether there are any benefit limitations applicable to this service or supply. This medical policy does not apply to Medicare Advantage.
Discrimination Is Against the Law

Premera Blue Cross complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, or sex. Premera does not exclude people or treat them differently because of race, color, national origin, age, disability or sex.

Premera:
- Provides free aids and services to people with disabilities to communicate effectively with us, such as:
  - Qualified sign language interpreters
  - Written information in other formats (large print, audio, accessible electronic formats, other formats)
- Provides free language services to people whose primary language is not English, such as:
  - Qualified interpreters
  - Information written in other languages

If you need these services, contact the Civil Rights Coordinator.

If you believe that Premera has failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability, or sex, you can file a grievance with:
Civil Rights Coordinator - Complaints and Appeals
PO Box 91102, Seattle, WA 98111
Toll free 855-332-4535, Fax 425-918-5592, TTY 800-845-5357
Email AppealsDepartment@Premera.com

You can file a grievance in person or by mail, fax, or email. If you need help filing a grievance, the Civil Rights Coordinator is available to help you.

You can also file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights, electronically through the Office for Civil Rights Complaint Portal, available at https://ocrportal.hhs.gov/ocr/portal/lobby.jsf, or by mail or phone at:
U.S. Department of Health and Human Services
200 Independence Avenue SW, Room 509F, HHH Building
Washington, D.C. 20201, 1-800-368-1019, 800-537-7697 (TDD)
Complaint forms are available at https://ocrportal.hhs.gov/ocr/portal/lobby.jsf, or by mail or phone at:
Office for Civil Rights Complaint Portal, available at https://ocrportal.hhs.gov/ocr/portal/lobby.jsf, or by mail or phone at:
U.S. Department of Health and Human Services
200 Independence Avenue SW, Room 509F, HHH Building
Washington, D.C. 20201, 1-800-368-1019, 800-537-7697 (TDD)

Getting Help in Other Languages

This Notice has Important Information. This notice may have important information about your application or coverage through Premera Blue Cross. There may be key dates in this notice. You may need to take action by certain deadlines to keep your health coverage or help with costs. You have the right to get this information and help in your language at no cost. Call 800-722-1471 (TTY: 800-845-5357).

Arabic (Arabic):

يوجد هذا الإشعار معلومات هامة. قد يحتوي هذا الإشعار معلومات مهمة بصيغة طبقة أو
العثمانية التي تركز الحقول على مجالات مختلفة على تطبيقات الصحة والسعادة في هذا الإشعار. قد تحتاج إلاأن إجراء في توازن مفيد للحفاظ على تحفيز الجماهير السعادة في فعالية الكيفية. يحمل كل الحقول على هذه المعلومات والمساعدة بناءً على اللغة الإنجليزية، ترجمة
800-722-1471 (TTY: 800-845-5357) للواتساب

Chinese (Chinese):

本通知有重要的讯息。本通知可能有關於您透過 Premera Blue Cross 提交的申請或保險的重要訊息。本通知可能有重要的日期。您可能需要在截止日期之前採取行動。以保留您的健康保險或費用補貼。您有權利免費以您的母語得到本訊息和協助。請撥電話 800-722-1471 (TTY: 800-845-5357)。
Premera Blue Cross or its subsidiary Premera Blue Cross Health Plan, Inc. (collectively "Premera Blue Cross") may contain important information about your application or coverage.

Please review Premera Blue Cross or any unit of Premera Blue Cross Health Plan, Inc. (collectively "Premera Blue Cross") for additional or different terms.

Este aviso puede contener información importante privada cuya revelación podría perjudicarle.

Premera Blue Cross or its subsidiary Premera Blue Cross Health Plan, Inc. (collectively "Premera Blue Cross") may contain important information about your application or coverage.

Please review Premera Blue Cross or any unit of Premera Blue Cross Health Plan, Inc. (collectively "Premera Blue Cross") for additional or different terms.

Este aviso puede contener información importante privada cuya revelación podría perjudicarle.